- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting transcription factors in acute myeloid leukemia
Authors
Keywords
Transcription factor, Acute myeloid leukemia, Differentiation, Granulocyte
Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-06-28
DOI
10.1007/s12185-018-2488-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MYB – A regulatory factor in hematopoiesis
- (2018) Xunde Wang et al. GENE
- Genetic regulation of the RUNX transcription factor family has antitumor effects
- (2017) Ken Morita et al. JOURNAL OF CLINICAL INVESTIGATION
- Pharmacological inhibition of the transcription factor PU.1 in leukemia
- (2017) Iléana Antony-Debré et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting acute myeloid leukemia by drug-induced c-MYB degradation
- (2017) V Walf-Vorderwülbecke et al. LEUKEMIA
- A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood
- (2017) A R Lourenço et al. ONCOGENE
- ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia
- (2017) Carolina Yaeko Namasu et al. Oncotarget
- Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2
- (2017) Sreeja Karathedath et al. PLoS One
- Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells
- (2016) B Mitton et al. LEUKEMIA
- Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells
- (2016) Sagar Uttarkar et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of NRF2–ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells
- (2016) Hui Peng et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters
- (2016) Bryan Mitton et al. Oncotarget
- Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction
- (2015) Sagar Uttarkar et al. BLOOD
- Direct and indirect targeting of MYC to treat acute myeloid leukemia
- (2015) Sam Brondfield et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia
- (2015) K. Seipel et al. CLINICAL CANCER RESEARCH
- C/EBPα in normal and malignant myelopoiesis
- (2015) Alan D. Friedman INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors
- (2015) Andrea Cercek et al. INVESTIGATIONAL NEW DRUGS
- Targeting novel signaling pathways for resistant acute myeloid leukemia
- (2015) Kathleen M. Sakamoto et al. MOLECULAR GENETICS AND METABOLISM
- Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia
- (2015) Florian Grebien et al. Nature Chemical Biology
- RNA activation: Promise as a new weapon against cancer
- (2014) Lin Zheng et al. CANCER LETTERS
- SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
- (2014) S. Wang et al. CANCER RESEARCH
- Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics
- (2014) Bing-Jia Chen et al. International Journal of Biological Sciences
- Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells
- (2014) Nicholas Don-Doncow et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
- (2014) Daqing Sun et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
- (2014) Yujun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer
- (2014) Dimitris Stellas et al. JNCI-Journal of the National Cancer Institute
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesisin vivo
- (2013) Vikash Reebye et al. HEPATOLOGY
- Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis
- (2012) H. Guo et al. BLOOD
- RUNX family: Regulation and diversification of roles through interacting proteins
- (2012) Linda Shyue Huey Chuang et al. INTERNATIONAL JOURNAL OF CANCER
- The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy
- (2011) Mauro Savino et al. PLoS One
- Current strategies to target p53 in cancer
- (2010) Fang Chen et al. BIOCHEMICAL PHARMACOLOGY
- Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006–2010
- (2009) D. Pulte et al. ANNALS OF ONCOLOGY
- Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3
- (2007) Rebecka Hellsten et al. PROSTATE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search